MERCK & CO, INC. for MERCK & CO INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418, Animal Drug User Fee Amendments of 2023 H.R. 1503, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2873, (117th Cong.) Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3932/S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1712, (116th Cong.) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2021 or the PASTEUR Act of 2021 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to: 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Prescription drug cost-sharing; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; Intellectual property and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Pharmacy Benefit Manager (PBM) policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMELIA BREINIG New | Dir. of Intergovernmental Affairs and Public Engagement, Executive Office of the President; Deputy Press Secretary, Senate finance Committee; Press Aide, Press Secretary, Rep. Terry; Staff Asst., Sen. Fischer |
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| ADAM HUFTALEN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Medicare/Medicaid MMM
H.R. 5376, (117th Cong.) Build Back Better Act S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 Issues relating to: Medicaid; Medicare; Medicare Part B and D drug pricing issues; Medicare Part D, Six Protected Classes; Prior authorization process under Medicare Advantage plans; 340B program integrity; 340B of the Public Health Services Act; 340B drug pricing program; Drug Pricing; FY-2023 Budget and Appropriations Legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERIN DARLING | — |
| ROBERT FILIPPONE | — |
| ADAM HUFTALEN | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Taxation/Internal Revenue Code TAX
Issues related to: Tax reform and tax policy, generally; Tax Cuts and Jobs Act of 2017 (P.L. 115-97); Inflation Reduction Act (P.L. 117-169), provisions relating to taxes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FILIPPONE | — |
| BRADLEY ALLEN ROSSIN | — |
| ELIZABETH SCHWARTZ | — |
| BRADFORD TALLAMY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.